Optipharm CEO Hyunil Kim Increases Stake to 2.09% via Small Open-Market Purchases... Routine Disclosure with Negligible Shareholder Impact
Representative director Hyunil Kim purchased an additional 2,000 shares (average price 4,956 KRW) through open market transactions from May 21 to 29, 2026, increasing his holdings to 306,650 shares and raising his stake from 2.08% to 2.09%, a 0.01%p increase.
This buy was a personal open-market purchase, not a share repurchase, with a total acquisition cost of approximately 9.91 million KRW, resulting in negligible financial impact.
[AI Comprehensive Analysis]While insider buying by the CEO may send a positive signal to the market, the minimal 0.01%p change in stake has no material effect on shareholder value. It should be interpreted as a personal portfolio adjustment rather than a change in corporate strategy; investors should exercise caution.
KOSDAQ Filing Information
Filing: Report on Ownership of Specific Securities by Executives and Major Shareholders